Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.51 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13973636 | 0.90 | MAPK10 (0.51) | FABP3FABP4MAPTSMN1; SMN2TP53 | |
| SCHEMBL13973637 | 0.89 | NPC1 (0.58) | MAPTSMN1; SMN2TP53PKMHTT | |
| SCHEMBL13961569 | 0.89 | NPC1 (0.46) | FABP3FABP4MAPTSMN1; SMN2TP53 | |
| SCHEMBL4486500 | 0.88 | TACR3 (0.51) | MAPTSMN1; SMN2TP53HTTNPC1 | |
| SCHEMBL13973657 | 0.88 | MAPT (0.48) | FABP3FABP4MAPTSMN1; SMN2TP53 | |
| SCHEMBL5207273 | 0.86 | AKR1C3 (0.46) | MAPTSMN1; SMN2TP53PKMDHODH | |
| SCHEMBL13973659 | 0.86 | MAPT (0.44) | FABP3FABP4MAPTSMN1; SMN2TP53 | |
| SCHEMBL4484788 | 0.85 | AKR1C3 (0.46) | MAPTSMN1; SMN2TP53AKR1C3AKR1C2 | |
| SCHEMBL4478341 | 0.85 | CDC25B (0.52) | MAPTSMN1; SMN2HTTAKR1C3AKR1C2 | |
| SCHEMBL4481316 | 0.85 | CSNK2A1 (0.41) | FABP3FABP4MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372654-A4 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORP (US) | 2007-10-03 | — | — | EP | claimed |
| US-7087758-B2 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | claimed |
| EP-1372654-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2002081728-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | claimed |
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1372654-A4 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORP (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1556379-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| US-7087758-B2 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | disclosed |
| EP-1556379-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004034985-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1372654-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002081728-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | HIPK3, HIPK1, HYPK | FABP3 1438/4885FABP4 4570/4885MAPT 1202/4885 |
| US-20060106058-A1 | Chemical compounds | YARS1, DAPK3, NEK3 | FABP3 3871/4885FABP4 4681/4885MAPT 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.